Nachrichten zur Abbvie Inc. Aktie

AbbVie ist ein führender Biopharma-Konzern und ersetzt den Humira-Rückgang zunehmend mit neuen Wachstumstreibern aus Immunologie, Neurologie und Onkologie. Skyrizi…

GOOGL, MA and ABBV headline todays research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks.…

AbbVie bets on pipeline diversification amid patent cliffs, while J&Js higher profitability masks litigation risks, a choice between growth ambition…

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and…

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran…

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly…

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.…

These companies are committed to rewarding shareholders.…

AbbVie’s Rinvoq wins EU approval for pediatric arthritis…

AbbVies market-beating days dont seem to be over yet.…

Citadel, Ken Griffins hedge fund, materially increased its stake in AbbVie; heres why you may want to follow that lead.…

The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.…

ABBVs atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.…

AbbVies diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.…

ABBVs Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.…

…

BERLIN (dpa-AFX) - Immer mehr Menschen lassen minimalinvasive Eingriffe beim Schönheitschirurgen durchführen. Zu minimalinvasiven Eingriffen gehören…